Abstract 1169P
Background
Acral lentiginous melanoma (ALM), although overall a rare type of melanoma, is the most common form of the disease in a number of countries in Latin America, Africa, and Asia; it is associated with a poor prognosis and recurrence. In this study, we seek to gain a better understanding of the tumor-immune components of ALM and their relationship to transcriptional programs.
Methods
Tumour samples were collected from patients undergoing treatment at the National Cancer Institute of Mexico, and have been annotated with vast clinical information. We performed transcriptome sequencing through exome-capture bulk RNA-sequencing on 65 primary tumors from 64 Mexican patients, and did spatial protein profiling using a tissue microarray on 110 tumor segments from 45 patients. Samples were collected at the National Cancer Institute of Mexico and have been annotated with vast clinical information.
Results
We identified differentially expressed genes such as CXCL8, MMP1, and TERT in ulcerated lesions. RNA deconvolution showed a high abundance of cancer-associated fibroblasts (CAFs) and the absence of NK cells. Consensus clustering identified three ALM subgroups based on global gene expression. Integration of spatial protein information confirmed the high abundance of CAFs- associated markers and the absence of CD56. Fibronectin, SMA, and the cancer stem cell marker CD44 were markedly elevated. We investigated expression patterns within particular regions of interest and found that fibronectin, VISTA, SMA, IDO1, CD34, CD45, CD3, HLA-DR, and CD45RO were differentially expressed in non-tumor regions, while tumor ROIs expressed B7-H3, CD127, GAPDH, and Ki-67 significantly at higher levels. Comparisons between RNA and protein for 35 targets are being conducted.
Conclusions
So far, our analyses point to genes that could drive important prognostic characteristics. We confirmed that ALM is characterized by an immunosuppressive tumor microenvironment. The role of CAFs and the mechanisms affecting NK cells require further research. The present project will enhance our understanding of the TME components and the antitumor response in an understudied disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Carla Daniela Robles Espinoza.
Funding
CONACyT A3-S-31603, UNAM PAPIIT IN209422, Welcome Sanger Institute International Fellowship, Melanoma Research Alliance Pilot Award #825924, William Guy Forbeck Research Foundation.
Disclosure
D. Adams: Other, Institutional, Other, DJA is supported by AstraZeneca, OpenTargets and is a paid consultant for Microbiotica: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1159P - Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801
Presenter: Pablo Cerezuela-Fuentes
Session: Poster session 13
1160P - Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight-adjusted dose, FLATIMEL study
Presenter: Iona Campo le Brun
Session: Poster session 13
1161P - Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data
Presenter: Madona SAKKAL
Session: Poster session 13
1162P - Prolonged exposure to proton pump inhibitors (PPI) at the time of initiation of immune checkpoint blockade (ICB) mediates better clinical outcomes in patients with metastatic melanoma
Presenter: Kyrillus Shohdy
Session: Poster session 13
1163P - CD39 affect the prognostic role of NLR via N2 neutrophils in metastatic melanoma patients treated with immunotherapy
Presenter: Domenico Mallardo
Session: Poster session 13
1164P - Changes of TCR repertoire in metastatic melanoma and renal cell carcinoma patients treated with nivolumab correlate with overall survival
Presenter: Martin Klabusay
Session: Poster session 13
1165P - Single cell spatial features of in-transit melanoma associated with patient outcome to immunotherapy
Presenter: Xinyu Bai
Session: Poster session 13
1166P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
Presenter: Giuseppe Tarantino
Session: Poster session 13
1168P - Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
Presenter: Jan-Malte Placke
Session: Poster session 13
1170P - Survival outcome prediction of primary melanoma tumours from histology images using deep learning
Presenter: Céline Bossard
Session: Poster session 13